Speeding up progress in biopharma and medical technology via innovation, financial support, and collaborations.
French chemist and microbiologist whose groundbreaking contributions to germ theory, vaccination, and pasteurization revolutionized medicine
GenBio intends to hold talks with pharmaceutical and biotech leaders in Singapore regarding its scientific platform and strategic prospects.
In the realm of observation, luck only benefits the mind that is prepared.”— Louis Pasteur
ALISO VIEJO, CA, UNITED STATES, August 1, 2026 /EINPresswire.com/ — GenBio Inc., a privately owned biotechnology firm focused on developing therapeutic and wellness products derived from uncommon,
scientifically defined natural bioactive compounds, has confirmed its participation in the
2026 Asia Bio Partnering Forum, scheduled for September 1–2 at Marina Bay Sands in Singapore.
Through the partneringONE® platform, GenBio’s leadership will be accessible for private discussions with pharmaceutical and biotech executives, corporate development groups, and other eligible strategic partners.
The firm is advancing a multidisciplinary scientific approach centered on detecting, purifying, and preparing naturally sourced bioactive compounds that show promise for addressing antimicrobial resistance, inflammation, and other human health concerns.
GenBio’s development pipeline consists of:
• An efflux pump inhibitor initiative exploring ways to counteract bacterial resistance mechanisms
and enhance the effectiveness of antimicrobials;
• A program for antibacterial discovery and drug repurposing, carried out in partnership with Hypha
Discovery in the United Kingdom;
• An anti-inflammatory development initiative backed by continuous scientific research in Australia; and
• Complementary health and wellness products stemming from the company’s wider bioactive
compound platform.
“Taking part in the Asia Bio Partnering Forum gives GenBio a valuable chance to connect directly with international pharmaceutical and biotechnology decision-makers,” stated Giles Tilley,
Chief Executive Officer of GenBio Inc. “The Asia-Pacific region is becoming more and more central to global life-sciences innovation, and Singapore offers an excellent venue for meaningful conversations about GenBio’s
research platform, development efforts, and long-term strategic outlook.”
GenBio is currently preparing for focused conversations regarding strategic opportunities tied to the
company and its scientific assets. Following management review and the signing of suitable confidentiality
agreements, qualified parties will gain access to due diligence materials that are released progressively.
“Partnering systems fill up very rapidly,” said Todd D. Sonoga, Director and Chief Marketing Officer of GenBio Inc. “By introducing GenBio before meeting scheduling begins, we aim
to give potential strategic partners enough time to learn about our scientific platform, examine our
company profile, and request a meeting with management.”
The Asia Bio Partnering Forum gathers biotech and pharma executives, corporate development experts, institutional investors, and emerging life-sciences companies from across the
Asia-Pacific region and worldwide markets. The partneringONE platform enables one-on-one meetings.
Eligible organizations wishing to meet with GenBio can find the company through partneringONE
once the platform goes live on August 4, 2026.
About GenBio Inc.
GenBio Inc. is a biotechnology company headquartered in the U.S. that creates next-generation antimicrobial, anti-inflammatory, and supplementary health products from uncommon natural bioactive compounds.
Collaborating with scientific partners in Australia and the United Kingdom, GenBio employs systematic compound identification, biological screening, and development research to turn naturally occurring bioactivity into commercially viable therapeutic and health opportunities.
Developed by Nature. Identified, Refined and Formulated by GenBio
